BMS starts strategic review of UPSA business

4 July 2018 - Deborah Wilkes

Archived

Bristol-Myers Squibb is considering a range of strategic options, including divestment, for its French consumer healthcare business UPSA.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: